Compare ResMed Inc. (RMD) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Upwork Inc — how do they compare? ResMed Inc. trades at $229.72 (market cap $31.89B), while Upwork Inc trades at $8.63 (market cap $1.07B). The key difference: ResMed Inc. is far larger — about 29.8× Upwork Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Upwork Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Upwork Inc for 38 Days on average.
| RMD | UPWK | |
|---|---|---|
Market Cap | $31.89B | $1.07B |
Volume | 618,314 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $277.88 | $22.11 |
52-Week Low | $182.82 | $7.84 |
Typical Hold Time | 51 Days | 38 Days |
Enterprise Value | $31.24B | $833.01M |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Upwork trades at $8.40, up 0.48% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 EPS of $0.41, beating expectations, but revenue guidance disappointed, causing a recent sell-off. Financials show strong gross margins of 77.21% and a P/E of 10.99, indicating potential undervaluation. Recent news includes insider selling and a securities fraud investigation, adding to investor caution.
The outlook is mixed: solid profitability and low valuation offer upside, but AI disruption risks and weak guidance pose challenges. Analysts are split with a $9.64 price target, suggesting moderate upside from current levels if execution improves and sentiment recovers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
